Gilead Sciences - Atripla

Therapeutic Area: Infectious Disease
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

As a joint venture, the two companies engaged Addison Whitney to develop and test trademark candidates for a triple combination product to treat HIV. This product, which combines BMS’ Sustiva and Gilead’s Truvada, was the first single pill, once daily, fixed dose combination HIV antiretroviral regimen to market. Addison Whitney created the name Atripla. An extensive research and analysis study was conducted in support of the name. The results were presented in a tradename submission document written by Addison Whitney and submitted by the sponsors to the regulatory bodies.

---

« BACK TO EXPERIENCE